Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-30

Apelin inhibition as an anti-cancer therapy

Objective

The spread of cancer is a major cause of mortality and morbidity throughout Europe and beyond. As the growth of solid tumours is dependent on the formation of a neovascular supply, inhibition of tumour-induced neoangiogenesis represents an actively pursued strategy to treat human cancers. Current anti-angiogenic therapies are, however, hampered by the onset of resistance through upregulation of additional angiogenesis factors. Therefore, the identification and study of these alternative neo-angiogenesis regulators as therapeutic targets is currently of key interest. Apelin is a potent angiogenic factor frequently found upregulated in cancer. However, the in vivo pathophysiological relevance of apelin function in cancer has not been addressed so far.

In this proposal, we intend to study apelin inhibition and function in spontaneous cancer models. We will take a multidisciplinary and entirely in vivo approach that will combine the power of mouse genetics with state-of-the-art analysis techniques. We will evaluate in parallel the function of apelin in cancer and the highly promising effectiveness of apelin inhibition as a therapeutic cancer target either alone or in a combined anti-angiogenesis therapy.

The relevance of de novo formation of lymphatic vessels in the progression of cancer has only recently been recognized. Using state-of-the-art techniques we will extend our studies by not only assessing the in vivo role of apelin in angiogenesis but also its involvement in lymphangiogenesis. Taken together, we believe that this project will shed new light on the role and function of a novel factor that regulates vessel formation in cancer and validate its potential as therapeutic target. If successful, our in vivo multidisciplinary study will open a new avenue for the treatment of resistant cancer cases and for the development of combinatorial anti-cancer therapies with higher efficiency and a reduced incidence of resistance formation.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-PEOPLE-2012-IEF
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

MC-IEF - Intra-European Fellowships (IEF)

Coordinator

INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH
EU contribution
€ 179 137,20
Address
DR BOHRGASSE 3
1030 WIEN
Austria

See on map

Region
Ostösterreich Wien Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0